Development of an irreversible covalent inhibitor of FMS-like tyrosine kinase receptor 3 for treating acute myeloid leukemia
Ended Project Grant Awarded Last action
- Award ID
- R41CA250761
- Recipient
-
Bridgene Biosciences Inc. UEI ECKNZL5KZVK7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $298,928
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Sunnyvale, CA 94089, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $298,928 |
Quick answers
Who received award R41CA250761?
R41CA250761 was awarded to Bridgene Biosciences Inc. by National Cancer Institute (National Institutes of Health) on September 18, 2020.
How much is award R41CA250761 worth?
$298,928 has been obligated on R41CA250761.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award